Telix Pharmaceuticals (TLX) Competitors $10.82 -0.07 (-0.64%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$11.07 +0.25 (+2.30%) As of 08/12/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock TLX vs. TEVA, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BBIO, VRNA, and BPMCShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Telix Pharmaceuticals (NASDAQ:TLX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media favor TLX or TEVA? In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Teva Pharmaceutical Industries and 10 mentions for Telix Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.09 beat Telix Pharmaceuticals' score of 0.35 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TLX or TEVA? Telix Pharmaceuticals presently has a consensus target price of $22.33, indicating a potential upside of 106.41%. Teva Pharmaceutical Industries has a consensus target price of $24.71, indicating a potential upside of 49.06%. Given Telix Pharmaceuticals' higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is TLX or TEVA more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Teva Pharmaceutical Industries -0.95%46.10%7.18% Do insiders and institutionals have more ownership in TLX or TEVA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, TLX or TEVA? Telix Pharmaceuticals has higher earnings, but lower revenue than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M7.09$32.93MN/AN/ATeva Pharmaceutical Industries$16.63B1.14-$1.64B-$0.16-103.63 SummaryTeva Pharmaceutical Industries beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.69B$3.00B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E RatioN/A19.9630.4025.31Price / Sales7.09344.96444.63101.62Price / Cash95.3640.7837.7258.50Price / Book9.667.658.306.01Net Income$32.93M-$54.75M$3.26B$265.10M7 Day Performance-9.61%0.95%1.48%1.39%1 Month Performance-32.25%8.12%3.66%2.43%1 Year PerformanceN/A10.97%40.98%24.74% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix PharmaceuticalsN/A$10.82-0.6%$22.33+106.4%N/A$3.69B$516.72M0.00N/AUpcoming EarningsTEVATeva Pharmaceutical Industries3.3478 of 5 stars$15.70+2.1%$24.71+57.4%-2.9%$17.64B$16.54B-98.1336,830Positive NewsGMABGenmab A/S3.7382 of 5 stars$21.98+0.9%$37.80+72.0%-17.5%$13.97B$3.12B12.492,682Positive NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.5415 of 5 stars$13.80-1.0%$16.95+22.9%-15.5%$11.64B$334.26B20.9027,811Positive NewsQGENQiagen3.4735 of 5 stars$50.27+0.7%$49.40-1.7%+11.3%$11.10B$1.98B126.045,765Analyst DowngradeAnalyst RevisionMRNAModerna4.3604 of 5 stars$27.64+0.1%$45.61+65.0%-68.4%$10.68B$3.24B-3.675,800ASNDAscendis Pharma A/S2.6347 of 5 stars$184.15+5.5%$223.67+21.5%+52.5%$10.67B$393.54M-29.321,017Trending NewsEarnings ReportVTRSViatris1.7924 of 5 stars$8.94+1.5%$10.40+16.3%-12.5%$10.34B$14.74B-2.8232,000Earnings ReportBBIOBridgeBio Pharma4.4556 of 5 stars$47.75+0.8%$61.18+28.1%+104.0%$8.99B$221.90M-13.53400Trending NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share1.5523 of 5 stars$105.47+0.3%$109.00+3.3%+326.2%$8.95B$42.28M-52.7430Positive NewsEarnings ReportBPMCBlueprint Medicines0.5669 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640 Related Companies and Tools Related Companies TEVA Alternatives GMAB Alternatives RDY Alternatives QGEN Alternatives MRNA Alternatives ASND Alternatives VTRS Alternatives BBIO Alternatives VRNA Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access